GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Veritas In Silico 130A.T · JPY

N/A · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

240

-9.77%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Veritas In Silico

Its shares trade on Tokyo Stock Exchange under the ticker 130A.T. It has been listed since 8 February 2024. In the fiscal year to 31 December 2025, it reported revenue of ¥91.1m and a net loss of ¥425.7m. At that date it held total assets of ¥1.88bn and shareholders' equity of ¥1.78bn.

Veritas In Silico Inc is a JP-based company operating in industry. The company is headquartered in Shinagawa-Ku, Tokyo-To. The company went IPO on 2024-02-08. Veritas In Silico Inc is a Japan-based company primarily engaged in the pharmaceutical discovery platform business. The main business is small molecule drug discovery targeting messenger ribonucleic acid (mRNA) using the ibVIS platform, which integrates digital technology including in silico ribonucleic acid (RNA) structural analysis technology and drug discovery technology, through joint drug discovery research with pharmaceutical companies to create mRNA-targeted small molecule drugs.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
8 Feb 2024
Employees
14

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Veritas In Silico Inc operates a specialized pharmaceutical discovery platform in Japan.
  • The ibVIS platform integrates digital technology for RNA structural analysis effectively.
  • The company targets messenger ribonucleic acid using small molecule drug discovery methods.

Weaknesses

  • The firm employs only fourteen full-time staff members currently.
  • Veritas In Silico Inc is headquartered in Shinagawa-ku, Tokyo-To.
  • The company went public on 8 February 2024 recently.

Opportunities

  • Joint drug discovery research with pharmaceutical companies creates new revenue streams.
  • Creating mRNA-targeted small molecule drugs offers significant market potential.
  • Digital technology integration enhances the efficiency of drug discovery processes.

Threats

  • Operating in the pharmaceutical industry involves high regulatory compliance risks.
  • Competition from other drug discovery platforms may impact market share.
  • Reliance on joint research partners could limit independent innovation speed.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.